Kala Bio Inc (NAS:KALA)
$ 6.825 -0.04 (-0.58%) Market Cap: 19.22 Mil Enterprise Value: 4.76 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 49/100

Kala Pharmaceuticals Inc STRIDE 3 Data Conference Call Transcript

Mar 09, 2020 / 12:00PM GMT
Release Date Price: $396.5 (+26.27%)
Operator

Good morning, and welcome to Kala Pharmaceuticals Conference Call to discuss the STRIDE 3 clinical trial results. (Operator Instructions) As a reminder, this call is being recorded. I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran
Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator, and thank you all for participating in today's call. Please note that the press release we issued earlier today and the presentation that we're using for this conference call are both available on the Investors and Media section of the Kala website, www.kalarx.com. Additionally, today's call is being webcast live.

Joining me from the company today are Mark Iwicki, Chairman, President and Chief Executive Officer; Kim Brazzell, Chief Medical Officer; Todd Bazemore, Chief Operating Officer; Mary Reumuth, Chief Financial Officer; and Hongming Chen, Chief Scientific Officer.

Turning to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot